Scholarlink

Introduction <p>This study aimed to assess the morphological and functional effects of faricimab in patients with chronic diabetic macular edema (DME) who had an insufficient response to previous treatments.</p> Methods <p>We conducted a single-center, retrospective study including eyes with pretreated chronic DME that were switched to faricimab and received at least three injections. The main outcome measures were central subfield thickness (CST) and best-corrected visual acuity (BCVA) changes before and after switching to faricimab.</p> Results <p>Twenty-two eyes from 18 patients were analyzed, with a mean pretreatment period of 5.7&#xa0;years. Most eyes had been treated with two or more intravitreal agents. Before switching to faricimab, the mean CST was 468.5 ± 163.6&#xa0;µm, which decreased to 383.1 ± 125.3&#xa0;µm, 362.8 ± 93.4&#xa0;µm (<i>p</i> = 0.207), and 339.5 ± 94.3&#xa0;µm (<i>p</i> &lt; 0.001) after the first, second, and third injections, respectively. BCVA showed improvement from 0.48 to 0.37 logMAR after the third injection, though the change was only statistically significant after the first injection (<i>p</i> = 0.022).</p> Conclusions <p>The study demonstrated significant CST reduction in patients with chronic DME in a real-world setting, even after prolonged treatment, suggesting that faricimab can lead to morphological and functional benefits in these cases. Further data are needed to explore the real-world, long-term effects and durability of faricimab in chronic DME.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-World Data on Morphological and Functional Responses After Switching to Faricimab in Recalcitrant, Chronic Diabetic Macular Edema

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月12日

查看全文
  • Viktoria Deiters,
  • Anna Lorger,
  • Franziska Eckardt,
  • Jakob Siedlecki,
  • Benedikt Schworm,
  • Siegfried G. Priglinger,
  • Tina R. Herold

摘要

Introduction

This study aimed to assess the morphological and functional effects of faricimab in patients with chronic diabetic macular edema (DME) who had an insufficient response to previous treatments.

Methods

We conducted a single-center, retrospective study including eyes with pretreated chronic DME that were switched to faricimab and received at least three injections. The main outcome measures were central subfield thickness (CST) and best-corrected visual acuity (BCVA) changes before and after switching to faricimab.

Results

Twenty-two eyes from 18 patients were analyzed, with a mean pretreatment period of 5.7 years. Most eyes had been treated with two or more intravitreal agents. Before switching to faricimab, the mean CST was 468.5 ± 163.6 µm, which decreased to 383.1 ± 125.3 µm, 362.8 ± 93.4 µm (p = 0.207), and 339.5 ± 94.3 µm (p < 0.001) after the first, second, and third injections, respectively. BCVA showed improvement from 0.48 to 0.37 logMAR after the third injection, though the change was only statistically significant after the first injection (p = 0.022).

Conclusions

The study demonstrated significant CST reduction in patients with chronic DME in a real-world setting, even after prolonged treatment, suggesting that faricimab can lead to morphological and functional benefits in these cases. Further data are needed to explore the real-world, long-term effects and durability of faricimab in chronic DME.